Navigation Links
Benitec MOU With CalbaTech, Inc.
Date:8/19/2007

hat have been banked by HIV patients and send those treated cells to a patient's treating physician for re-injection. CalbaTech would pay to Benitec a fee for using the protocols developed for the treatment of the stem cells.

CalbaTech's new subsidiary, TherapyStem, Inc., has created a patent-pending., process to harvest stem cells from HIV infected individuals to be cryopreserved for future transplantation into a client for medical purposes. All other stem cell collection services exclude the collection, processing and storage of blood from individuals with HIV. As the business of TherapyStem develops, the company also believes that it will be able to collect, process and store stem cells from umbilical cords that have come from a mother that has HIV. Those cords are currently excluded from collection by cord blood companies.

CONTACT:

BENITEC LTD

Sue MacLeman Rudi Michelson

Chief Executive Officer Monsoon Communications

+61 437 211 200 +61 411 402 737

About Benitec

Benitec is an Australian biotechnology company focused on licensing its extensive intellectual property portfolio and developing therapeutics to treat serious diseases using its proprietary ddRNAi technology. Its current therapeutic program is focused on Human Immunodeficiency Virus (HIV). Benitec's RNA-based HIV therapeutic, co-developed with City of Hope in Duarte, California, is currently in Phase I trial at City of Hope. For additional information, please visit http://www.benitec.com.

Paul Knopick

E & E Communications

949/707-5365

About CalbaTech

CalbaTech, Inc. (OTC Bulletin Board: CLBE) is an emerging life sciences company (http://www.CalbaTech.com) concentrating on providing products and platforms to the research market for biotech and pharmaceutic
'/>"/>

SOURCE Benitec Limited; CalbaTech, Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4

Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Democratic National Committee Chairman Tim Kaines Statement on the Senates Vote to Proceed to Full Floor Debate of Health Insurance Reform Legislation 61882 1Democratic National Committee Chairman Tim Kaines Statement on the Senates Vote to Proceed to Full Floor Debate of Health Insurance Reform Legislation 61882 2ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries 6448 1ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries 6448 2ASTMH Symposium Showcases Efforts To Meet the Need for New Medicines to Treat Infectious Diseases in Developing Countries 6448 3IntelliSoft Group and Amerinet Inc Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care 61876 1IntelliSoft Group and Amerinet Inc Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care 61876 2